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ABSTRACT
Objective The aim of this study was to identify the risk
factors associated with fragility fracture (FF) development in
glucocorticoid (GC)-treated patients.
Methods 127 patients (aged 62±18 years, 63% women)
on GC-treatment (mean dose 14.5±14.1 mg/day and
duration 47.7±69 months) were included. The clinical data
collected included bone metabolism study (including
gonadal axis), GC-treatment, disease activity, dual-energy
X-ray absorptiometry analysis (evaluating densitometric
osteoporosis (OP) and trabecular bone score (TBS) degraded
microarchitecture values (DMA)), X-ray (assessing vertebral
fractures (VF)), FRAX risk (GC-adjusted) and previous FF.
Results 17% of the patients had VF, 28% FF (VF and/
or non-VF), 29% OP and 52% DMA. Patients with VF
received more GC boluses (57.1% vs 29.5%, p=0.03),
were older (68±13 vs 60±19 years, p=0.02),
postmenopausal (100% vs 67%, p=0.02), had low
testosterone levels (57% vs 11%, p=0.02), lower TBS
values (1.119±0.03 vs 1.237±0.013, p<0.001) and
higher FRAX risk (17.2±16 vs 9.3±7.6, p=0.003).
Patients with FF showed higher accumulated GC doses
(16.6±18.4 vs 11.1±12.9 g, p=0.046). On multivariate
analysis, hypogonadism (OR 12.38; 95% CI 1.85 to
>100, p=0.01) and having received GC boluses (OR
3.45; 95% CI 1.04 to 12.15, p=0.01) were the main
factors related to VF. Hypogonadism (OR 7.03; 95% CI
1.47 to 38.37, p=0.01) and FRAX >20 (OR 7.08; 95%
CI 1.28 to 53.71, p=0.02) were factors related to FF.
Conclusion Hypogonadism is the principal risk factor for
developing fractures in GC-treated men and women,
whereas receiving GC boluses is a major factor for VF. These
results indicate the importance of evaluating the gonadal
axis in these patients.
INTRODUCTION
Glucocorticoids (GCs) constitute one of the
principal treatments of chronic inflammatory
disorders, including several rheumatic dis-
eases, with more than 1% of the general
adult population receiving chronic GC
treatment.1–5 Prolonged and/or high-dose
treatment can be associated with several
adverse effects, such as the development of
osteoporosis (OP) and fractures. Indeed,
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What is already known about this subject?
► Glucocorticoid-induced osteoporosis (GIOP) is the
most common form of secondary osteoporosis.
Fractures in GIOP frequently occur with higher
bone mineral density (BMD) than expected and
typically at the beginning of glucocorticoid (GC)
treatment, complicating the identification of
patients at risk for fracture.
What does this study add?
► This study analyses the risk factors associated with
the presence of fragility fractures in GC-treated
patients. Hypogonadism (menopausal women or
low testosterone levels in men) and having a FRAX
score for a major osteoporotic fracture >20 were the
main factors related to the presence of fragility
fractures, whereas patients with only vertebral
fractures (VF) more frequently were hypogonadal
and had received GC boluses.
► Patients with degraded microarchitecture in trabecular
bone score (TBS) (values <1.230) have a threefold
increased risk of VF.
How might this impact on clinical practice?
► As hypogonadism is the principal risk factor for
developing fractures in GC-treated men and
women, study of the gonadal axis in these
patients should be taken into consideration in
clinical practice. In addition, our results highlight
the need to evaluate preventive antiosteoporotic
treatment in these subjects, especially when
receiving GC bolus(es).
► Evaluation of TBS and FRAX can improve the
identification of high risk subjects, and thus, the
therapeutic approach.
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glucocorticoid-induced osteoporosis (GIOP) is one of
the most frequent causes of secondary OP and is
present in up to 30–50% of the GC-treated patients.
Age, GC doses and treatment duration are the main
factors related to its development.1–6 Nonetheless,
despite the frequency of this complication, GIOP
remains underdiagnosed and thereby under-treated,
with <30% of the affected subjects receiving antios-
teoporotic treatment.1 5 This phenomenon may be
partly explained by the special characteristics of
GIOP. Thus, GC-treated patients have a high risk of
fractures, particularly vertebral fractures (VF).
Indeed, the development of VF is markedly increased
in early periods of GC therapy, especially when high
GC doses are used.1–7 In addition, although low bone
mineral density (BMD) is a well-known factor for
developing fractures in GC-treated subjects, VF fre-
quently occur with relatively normal BMD values,
making identification of high-risk subjects
difficult.1–6 8 9 In this sense, our group recently
reported the utility of including trabecular bone
score (TBS) measurement to improve the evaluation
of patients at risk of fracture in this cohort of
patients.10 11 The identification of patients at risk is
also difficult using other assessment tools such as the
FRAX algorithm, which must be adjusted for GC
doses to improve its predictive yield.3 Moreover,
whereas menopausal status seems to be an additional
risk factor for fracture development in these subjects,
the role of hypogonadism in males with GIOP has
been scarcely analysed.12
VF constitute the most common type of fracture in
GIOP, affecting up to 50% of the GC-treated patients.1–5
These fractures are frequently overlooked and thus,
underdiagnosed, making identification of these patients
even more difficult.13–15 Thus, it is crucial to improve the
identification of subjects treated with GC at high risk for
fracture and in whom preventive antiosteoporotic ther-
apy would be indicated.
Therefore, the aim of this study was to analyse the
clinical characteristics and identify the risk factors asso-
ciated with the development of fragility fractures (FFs),
particularly VF, in GC-treated patients. We evaluated not
only clinical factors but also dual-energy X-ray absorptio-
metry (DXA) measurements (BMD and TBS) and bio-
chemical parameters of bone metabolism.
METHODS
Study design
We conducted a cross-sectional study fromAugust 2017 to
April 2018 including consecutive adult patients on
chronic GC treatment (≥5 mg/day of prednisone or
equivalent, for >3 months) for a rheumatological auto-
immune disease.
All patients provided written informed consent to par-
ticipate and the study was approved by the Ethics Com-
mittee of the Hospital Clínic (Reg. HCB/2017/0457).
Assessments
Clinical assessment included medical history focusing on
OP risk factors, the presence of menopause (defined as
the cessation of menstruation for ≥12 months and con-
sidered as the presence of hypogonadism in women), self-
reported history of low-impact trauma fractures (includ-
ing location), falls in the previous year, autoimmune dis-
ease duration and activity, previous and/or present
antiosteoporotic treatment, GC doses (daily current
dose, duration, cumulative, maximum GC dose and
bolus administration of prednisone or equivalent
received) and the use of additional immunosuppressant
agents. Anthropometric data (height, weight, body mass
index (BMI, kg/m2)) were also collected. Additionally,
FRAX (GC-adjusted3) scores were calculated.
Blood samples were obtained between 08:00 and 10:00
after overnight fasting, and included acute phase reactants
(erythrocyte sedimentation rate (ESR) and Creactive pro-
tein (CRP)), serum creatinine, glomerular filtration rate
(GFR), total alkaline phosphatase, calcium, phosphate,
thyroid function test, plasma parathyroid hormone
(PTH) and serum 25-hydroxyvitamin D (25(OH)D) levels
(determined by Atellica Solution (Siemens Healthineers,
Tarrytown, NY, USA) and Liaison analyser (DiaSorin, Salu-
ggia, Italy), respectively). Additionally, gonadotropins and
total testosterone were measured in men (determined by
Atellica Solution (Siemens Healthineers) and Roche
Elecsys testosterone II assay with the Cobas e601 analyser
(Roche Diagnostics, Mannheim, Germany), respectively).
Hypogonadism was defined by testosterone levels <250
ng/dL.16 Biochemical bone turnover markers were also
analysed, including serum procollagen type I amino-
terminal propeptide, as a marker of bone formation, and
the cross-linked C-terminal telopeptide of type I collagen,
as a marker of bone resorption, both measured with the
Cobas e601 analyser (Roche Diagnostics).
BMD (g/cm2) of the lumbar spine, femoral neck and
total hip was assessed by DXA (Lunar Prodigy, General
Electric Medical Systems, WI, USA). The coefficients of
variation for total femur and lumbar spine in our centre
are 0.6 and 0.8, respectively. Densitometric OP was
defined according to the WHO criteria with T-score
values ≤−2.5 (in subjects ≥50 years) or Z-score values <−2
(in subjects <50 years).17–19
The TBS was calculated using TBS iNsight software
(version 3.0.2.0) (Medimaps group, Geneva, Switzerland)
on the DXA lumbar spine images. A TBS value <1.230 was
considered as degraded microarchitecture (DMA).10 20
Standard radiographs of the thoracic and lumbar spine
were obtained to analyse the presence of VF. A VF was
defined as a reduction of 20% or more in the anterior,
middle or posterior height of the vertebral body com-
pared with adjacent, undeformed vertebrae.21
Statistical analysis
Statistical analyses were performed using R v3.5.3 (R Core
Team, 2019).22 Quantitative variables were described
using mean and SD, whereas frequencies and percentages
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were reported for qualitative variables. We analysed the
factors for VF and also for all FFs, the latter including VF
plus previous non-VF fractures (VF and/or non-VF). The
association with qualitative covariates was assessed using the
?2 test and Fisher’s exact test when applicability conditions
were not met. Adjusted ORs and p values were obtained by
applying logistic regression models. The association with
quantitative covariates was assessed by comparing the
means using t-tests. Linear models were used when adjust-
ment for confounding covariates was needed. Results were
considered as significant if p<0.05 except for the case of
multivariatemodel analysis where a p<0.1 was considered as
sufficient to keep the covariates in the model.
RESULTS
A total of 127 patients (63% women, 72.5% being post-
menopausal) with a mean age of 61.5±17.9 years (range
18–89) on chronic treatment with GC were included. The
mean GC dose at inclusion was 14.5±14.1 mg/day of
prednisone, received during 47.7±68.9 months (range
3–348). The most frequent associated autoimmune dis-
eases were systemic vasculitis (43%), polymyalgia rheu-
matica (19%), inflammatory myopathies (12%) and
systemic lupus erythematosus (8%), with other miscella-
neous disorders in the remaining patients (18%). Among
the latter, there were very few patients with rheumatoid
arthritis (RA) due to the low GC doses currently used.
Twenty-one patients (17%) had VF, and 36 (28%) had
any FF (VF and/or non-VF), being the radius, tibia,
humerus and metatarsal stress fractures the most fre-
quent non-VF. Thirty-seven patients (29.1%) had densito-
metric OP, 66 (52%) had DMA in the TBS measurement
(TBS<1.230) and 53 (41.7%) had or were receiving anti-
osteoporotic treatment. Table 1 shows the clinical char-
acteristics of the patients. At inclusion, the mean FRAX
risk scores (GC-adjusted3) were 10.8±10.1% and 4.9
±8.3% for major osteoporotic fracture and hip fracture,
respectively, in the patients over 40 years old.
When comparing patients with and without VF, those
with VF were older (68.0±12.8 vs 60.1±18.6 years, p=0.02),
had more frequently received GC boluses (57.1% vs
29.5%, p=0.03), showed more deteriorated kidney func-
tion (higher creatinine serum levels and a lower GFR),
lower BMD and T-score values at the lumbar spine and
total hip, and a higher frequency of DMA values by TBS
(table 1). Moreover, women with VF were all postmeno-
pausal, and most males with VF had low testosterone
levels (~60%). Subjects with VF also presented higher
adjusted FRAX risk scores for major osteoporotic fracture
(17.2% vs 9.3%, p=0.003) (table 1) and more frequently
showed values >20 (OR 5.47; 95% CI 1.41 to 21.22,
p=0.019), in addition to a trend towards more frequently
having values >10 (OR 2.85; 95% CI 1.05 to 7.73,
p=0.064). No differences in the frequency of previous or
present antiosteoporotic treatment were observed. When
patients with any FF (VF and/or non-VF) were compared
with those without fractures, most findings were similar to
those in subjects with VF (hypogonadism, older age and
lower BMD and TBS values) (table 1). Additionally, these
subjects showed higher accumulatedGCdoses (16.6±18.4
vs 11.1±12.9 g, p=0.0461), a trend towards more fre-
quently having fallen during the previous year (OR 2.37;
95% CI 1.07 to 5.24, p=0.051), higher indices of disease
activity (CRP values, 1.2±1.8 vs 0.7±1.4 mg/dL, p=0.045)
and higher FRAX scores for hip fracture (7.7±12.9 vs 3.6
±4.4, p=0.01) (table 1). Conversely, BMI, bone turnover
markers, PTH or 25(OH)D serum levels were not asso-
ciated with the presence of VF or any FF. No differences
in the indices of disease activity (ESR and CRP) were
observed when we compared patients who did or did
not receive GC boluses (ESR 24.8±27.5 vs 19±19.8 mm/
hour, p=0.304; CRP 0.98±1.74 vs 0.72±1.40 mg/dL,
p=0.411, respectively).
On comparing males with normal and low serum tes-
tosterone values (<250 ng/dL), hypogonadal males
showed higher BMI values (29.4±2.2 vs 26.3±2.7,
p=0.005) and indices of disease activity (ESR values, 23.1
±12.7 vs 12.3±14.1 mm/hour, p=0.0054). Hypogonadal
males also had lower lumbar TBS values (1.142±0.12 vs
1.265±0.12, p=0.014) and more frequently had DMA
(87.5% vs 42.9%, p=0.046) and a lower GFR (74.9±21.3
vs 83.0±11.9 mL/min, p<0.001). No differences in age,
doses and duration of GC treatment, falls during the
previous year, bone turnover markers or BMD values were
observed between the two groups of patients (table 2).Most
patients with hypogonadism (7/8, 87.5%) presented
increased gonadotropin values, indicative of hypergonado-
throphic hypogonadism. Three subjects were previously
treated (1) or under (2) immunosuppressive therapy
(methotrexate, mycophenolate mofetil (none with cyclo-
phosphamide (CYC))). Patients with low testosterone levels
(eight subjects) more frequently presented VF (4/8 (50%)
vs 3/34 (9%), p=0.017) and any type of FF (4/8 (50%) vs 5/
35 (14%), p=0.046) than those with normal testosterone
values.
In the multivariate analysis that included previous GC
boluses, the presence of densitometric OP, DMA and
hypogonadism, kidney function, CRP values and the
FRAX index for major osteoporotic fractures, the princi-
pal risk factors related to the presence of VF were the
presence of hypogonadism (OR 12.38; 95% CI 1.85 to
>100, p=0.01) and having received GC boluses (OR 3.45;
95%CI 1.04 to 12.15, p=0.01); whereas having a degraded
TBS was nearly significant (OR 2.36; 95%CI 0.51 to 12.97,
p=0.06). The principal risk factors for any FF were again
having hypogonadism (OR 7.03; 95% CI 1.47 to 38.37,
p=0.01) and a FRAX index >20 for major osteoporotic
fractures (OR 7.08; 95% CI 1.28 to 53.71, p=0.02). The
analysis was adjusted for age (<50, between 50–65 and
≥66 years), BMI, CRP and gender (table 3).
DISCUSSION
This study shows several interesting and useful data
related to risk factors for fracture in GC-treated patients.
Osteoporosis
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Age (years, mean±SD) 61.5±17.9 68.0±12.8 60.1±18.6 0.02 66.7±12.7 59.4±19.3 0.01
Gender (F/M, n) 80/47 13/8 67/38 1 26/10 54/37 0.25
Menopause, n (%) 58 (72.5) 13 (100) 45 (67.2) 0.02 24 (92.3) 34 (63.0) 0.01
BMI (kg/m2, mean±SD) 26.7±4.6 27.4±3.9 26.6±4.8 0.45 27.9±3.9 26.3±4.9 0.07
Autoimmune disease duration (months,
mean±SD)
61.9±98.8 63.4±84.1 62.0±102.1 0.95 65.7±87.8 60.4±103.2 0.5
Osteoporosis risk factors
Current smoking,n (%) 14 (11) 4 (19.1) 10 (9.5) 0.17 4 (11.1) 10 (11) 0.985
Alcohol≥3 units/day, n (%) 1 (0.8) 0 (0) 1 (0.95) 1 0 (0) 1 (1.1) 0.735
Fractured hip in parents, n (%) 16 (12.8) 4 (20.0) 12 (11.5) 0.29 5 (14.3) 11 (12.2) 0.77
Treatment
Current GC dose (mg/day, mean±SD) 14.5±14.1 14.9±16.3 14.4±13.8 0.89 12.8±13.7 15.1±14.3 0.4
GC treatment duration (months, mean
±SD)
47.7±68.9 55.4±81.8 46.4±66.5 0.60 62.2±86.3 41.9±60.2 0.29
Cumulative GC dose (g, mean±SD) 12.7±14.8 13.4±12.9 12.6±15.2 0.17 16.6±18.4 11.1±12.9 0.046
Intravenous GC boluses, n (%) 43 (33.9) 12 (57.1) 31 (29.5) 0.03 15 (41.6) 28 (30.8) 0.34
Immunosuppressant agents, n (%) 51 (40.2) 10 (47.6) 56 (53.3) 0.81 19 (53) 48 (53) 1
BMD
Lumbar spine T-score (mean±SD)* −0.84
±1.73
−1.62±0.37 −0.67±0.16 0.02 −1.45±1.34 −0.61±1.74 0.01
Femoral neck T-score (mean±SD)* −1.38
±0.99
−1.75±0.21 −1.30±0.09 0.053 −1.50±0.83 −1.33±0.96 0.36
Total hip T-score (mean±SD)* −1.10
±1.05
−1.51±0.22 −1.02±0.10 0.04 −1.26±0.96 −1.05±0.99 0.3
Densitometric osteoporosis, n (%) 37 (29.1) 8 (38) 29 (28) 0.48 13 (36.1) 24 (26.4) 0.38
TBS









Degraded microarchitecture, n (%) 66 (52) 16 (76) 49 (47) 0.02 25 (69.4) 41 (45.1) 0.02
Fractures
Patients with VF, n (%) 21 (16.6) – – – – – –
Patients with any fragility fracture, n (%) 36 (28.3) – – – – – –
FRAX risk




17.2±16.0 9.3±7.6 0.003 15.7±14.2 8.5±6.4 0.0002
FRAX for hip fracture (in patients
≥40 years old)
4.9±8.3% 9.3±14.9 3.9±5.6 0.13 7.7±12.9 3.6±4.4 0.01
Biochemical parameters
GFR (mL/min, mean±SD)† 77.6±17.8 81.4±5.1 90.0±2.7 0.005 86.1±4.1 89.8±2.9 0.73
ESR (mm/hour, mean±SD) 21.5±22.7 30.1±34.3 19.9±19.5 0.23 25.8±28.2 19.9±20.0 0.27
CRP (mg/dL, mean±SD) 0.8±1.5 1.2±2.0 0.7±1.4 0.09 1.2±1.8 0.7±1.4 0.045
PINP (ng/mL) 33.1±23.3 30.2±21.3 33.7±23.8 0.40 31.7±30.1 33.6±20.1 0.22
CTx (ng/mL) 0.34±0.2 0.39±0.3 0.34±0.2 0.38 0.34±0.3 0.35±0.2 0.30
25-hydroxyvitamin D (ng/mL) 27.6±15.4 26.4±15.4 28.0±15.5 0.60 28.8±13.5 27.1±16.1 0.34
Low testosterone values (<250 ng/dL;
in men, %)
8 (18.6%) 4 (57.1%) 4 (11.4%) 0.02 4 (44.4%) 4 (11.8%) 0.046
*Age- and BMI-adjusted values.
†Age-adjusted values.
BMD, bone mineral density; BMI, body mass index; CTx, C-terminal telopeptide of type I collagen; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; FF, fragility fracture; F, female; GC, glucocorticoid; GFR, glomerular filtration rate; M, male; OP, osteoporotic; PINP,
procollagen type I N-terminal propeptide; TBS, trabecular bone score; VF, vertebral fractures.
Bold values denote statistical significance at the p <0.05 level.
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Our results confirm the determinant role of gonadal
function in the development of either vertebral and/or
any FF, being the presence of hypogonadism the princi-
pal risk factor. This finding was observed not only in
women but also in men. Additionally, treatment with
GC bolus(es) was associated with an increased risk of VF
and the evaluation of TBS and FRAX improves the iden-
tification of high-risk subjects in whom preventive anti-
osteoporotic treatment should be indicated.
In general, most risk factors related to the development
of fractures in GC-treated patients coincide with those
reported in the general population.4 6 Advanced age is
also an important and well-recognised risk factor for
fracture in GC-treated subjects, particularly when com-
paring subjects aged over 60 years with young individuals.
Indeed, a previous study reported a relative risk for VF of
26 and a shorter interval between initiation of GC treat-
ment and the occurrence of fracture(s) in the older
population.23 In our series, patients with fractures were
older than non-fractured subjects. Nonetheless, although
age is a determinant factor for fractures, hypogonadism
was the principal risk factor for fracture.We observed that
all women with VF were postmenopausal and, although
the number of males was relatively small, most males with
VF were hypogonadal. In fact, in the multivariate analysis,
the presence of hypogonadism was the most important





Age (years, mean±SD) 64.5±16.7 69.4±13 0.38
BMI (kg/m2, mean±SD) 26.3±2.7 29.4±2.3 0.005
GC current dose (mg/day, mean±SD) 17.7±17 16.9±14.7 0.89
GC cumulative dose (g, mean± SD) 14.1±15.8 10.4±9 0.86
Intravenous GC boluses therapy, n (%) 11 (31.4) 2 (25) 1
Lumbar spine BMD (g/cm2) 1.161±0.27 1.220±0.31 0.59
Femoral neck BMD (g/cm2) 0.890±0.11 0.898±0.12 0.86
Total hip BMD (g/cm2) 0.942±0.13 0.973±0.13 0.53
Densitometric osteoporosis, n (%) 6 (17.1) 1 (12.5) 1
TBS (mean±SD) 1.265±0.12 1.142±0.12 0.01
Degraded microarchitecture, n (%) 15 (42.9) 7 (87.5) 0.046
GFR (mL/min, mean±SD)* 83.0±11.9 74.9±21.3 <0.001
ESR (mm/hour, mean±SD) 12.3±14.2 23.1±12.7 0.005
CRP (mg/dL, mean±SD) 0.49±1 0.88±1.2 0.09
PINP (ng/mL) 32.1±22.4 19.6±8.9 0.09
CTx (ng/mL) 0.31±0.19 0.25±0.11 0.67
25-hydroxyvitamin D (ng/mL) 27.8±113.3 22.1±7.5 0.39
*Age-adjusted values.
BMD, bone mineral density; BMI, body mass index; CRP, Creactive protein; CTx, C-terminal telopeptide of type I collagen; ESR, erythrocyte
sedimentation rate; GC, glucocorticoid; GFR, glomerular filtration rate; PINP, procollagen type I N-terminal propeptide; TBS, trabecular bone
score
Table 3 Multivariate analysis of the risk factors for fractures
Vertebral fractures Fragility fractures
OR (95% CI) P value OR (95% CI) P value
Hypogonadism 12.38 (1.85 to >100) 0.01 7.03 (1.47 to 38.37) 0.01
Intravenous GC boluses therapy 3.45 (1.04 to 12.15) 0.01 1.58 (0.55 to 4.50) 0.13
Densitometric osteoporosis 2.59 (0.49 to 16.27) 0.37 1.45 (0.45 to 4.55) 0.34
Degraded microarchitecture 2.36 (0.51 to 12.97) 0.06 1.65 (0.48 to 6.05) 0.12
FRAX for major OP fracture ≥20 4.56 (0.82 to 27.34) 0.08 7.08 (1.28 to 53.71) 0.02
Creatinine values 3.12 (0.60 to 19.90) 0.17 – –
Glomerular filtration rate 1.01 (0.94 to 1.08) 0.54 1.01 (0.98 to 1.05) 0.80
Age ≥65 years 0.66 (0.08 to 6.75) 0.67 0.62 (0.13 to 3.39) 0.64
CRP 1.03 (0.71 to 1.39) 0.39 1.09 (0.83 to 1.43) 0.24
The analysis was adjusted for age (analysing the data according to age <50, between 50–65 and ≥66 years), BMI, CRP and gender.
BMI, body mass index; CRP, C reactive protein; fragility fractures (VF+non-VF); GC, glucocorticoid; OP, osteoporosis; VF, vertebral fractures.
Osteoporosis
Florez H, et al. RMD Open 2020;6:e001355. doi:10.1136/rmdopen-2020-001355 5
 on F










pen: first published as 10.1136/rm






risk factor for fracture, with an OR of 12.38 for VF, which
remained significant after adjustment for different age
groups. Although previous studies have also described
the importance of menopausal status in the development
of fractures in GC-treated subjects, the evaluation of
hypogonadal status in GC-treated males has been scarcely
analysed, and recent data suggest that it could be more
frequent than expected.12 Indeed, nearly 20% of the
males in our study showed low testosterone levels, which
were frequently associated with increased gonadotropin
values indicative of primary hypogonadism in most cases.
On comparing hypogonadal males with those with nor-
mal testosterone levels, the former presented higher
indices of disease activity, with higher ESR values and
a lower GFR, and a higher BMI. No differences were
observed in either age or the mean GC exposure between
the two groups of patients. In addition, hypogonadal
males showed lower TBS values but similar BMD values
at the lumbar spine and femur. In previous studies, male
patients treated with GC and immunosuppressant agents,
especially CYC, presented decreased testosterone levels.12
This finding has also been attributed to the inflammatory
disease12 24 andmay explain the inhibitory effects at more
than one level of the hypothalamic–pituitary-–testicular
axis that can be observed in this type of patients.4 25–28
Whatever themechanism of hypogonadism in GC-treated
males, the present data suggest the need to evaluate
testosterone levels in these subjects. Moreover, the pre-
sent data also confirm the protective role of estrogens in
the development of GIOP in women. Thus, despite
receiving long-term treatment with high GC doses, none
of the premenopausal women included in this study
developed VF. Previous reports have also described this
finding.29 30 It should be highlighted that in the placebo
groups of several trials of antiosteoporotic therapy for
GIOP, the fracture incidence was increased in postmeno-
pausal women, but no fractures were observed in the non-
menopausal women, clearly suggesting a protective role
of estrogens in this type of OP.29–31 Considering this,
young women who become long-term amenorrheic dur-
ing GC treatment should be carefully assessed and likely
treated.
We also observed that previous treatment with GC
bolus(es) was associated with more than a threefold
increased risk of VF, even when adjusted for CRP values.
Indeed, patients with VF received GC boluses more fre-
quently than non-fractured patients. In addition, subjects
with any type of FF also received significantly higher
cumulated GC doses, further confirming the importance
of the magnitude and duration of GC therapy as determi-
nant factors for fracture development. In this sense, sev-
eral studies have reported a relationship between high
cumulatedGCdoses and an increase in fracture risk, being
particularly harmful, especially if maintained.1–6 32 Never-
theless, the effect of GC boluses on GIOP development is
controversial. Whereas some studies only reported a mild
effect on bone33–35 and even recommend its use to
decrease accumulated GC doses,36 other authors have
reported the harmful effects of GC boluses on bone
metabolism.37 The decrease in the inflammatory activity
of the disease induced by GC boluses may possibly have
played a role in these discordant results. Thus, systemic
inflammation is a well-recognised factor related to bone
loss and fractures, with several reports confirming the
protective effect of decreased inflammatory activity on
bone metabolism.4 Nevertheless, although we observed
higher indices of disease activity (with higher CRP values)
in fractured patients, which suggests a contributory role of
inflammation in this clinical condition, in the present
study, CRP values were not related to the presence of
fractures in the multivariate analysis. In addition, no dif-
ferences were observed when we compared the ESR and
CRP values between patients who did or did not receive
GC boluses. Although the use of GC boluses could have
interfered as a risk factor for inflammatory activity, our
results suggest that GC boluses seem to contribute to the
development of VF. Nevertheless, this point needs to be
better analysed in longitudinal studies addressed to this
subject.
Low BMD constitutes a well-established risk factor for
fracture. In GIOP, however, patients present skeletal frac-
tures at higher BMD values than expected. This finding
has been attributed to the additional effect of GC on bone
quality,1–6 with recent studies recommending TBS evalua-
tion in this process.10 11 38–44 This does not mean that
measuring BMD is not recommended, but rather that
additional analysis are needed to identify subjects at
risk. In fact, although we observed significantly lower
T-score values in the BMD of fractured patients, the pre-
sence of OP was low, with only 38% of the fractured
patients having OP. Conversely, as previously reported
by our group, fractured patients not only showed signifi-
cantly lower TBS values but also frequently presented
DMA, which was observed in 76% of the subjects with
VF. Indeed, patients with DMA had a greater than three-
fold increased risk of VF (OR 3.55; 95% CI 1 to 14.85,
p=0.049). These results confirm the usefulness of adding
TBS analysis to BMD measurement to better identify
patients at increased risk for fracture.10
In relation to the identification of patients at risk of
fracture, we also analysed the value of the FRAX algorithm
adjusted for GC treatment in patients >40 years of age. As
expected, patients with either VF or any type of fracture
showed significantly higher FRAX scores than non-
fractured subjects. Additionally, fractured patients more
frequently presented FRAX scores for a major osteoporo-
tic fracture >20, being indicative of high risk for fracture.
Indeed, in the multivariate analysis, this value (>20) sig-
nificantly increased the risk of any FF by nearly sevenfold,
further confirming the utility of FRAX in this population,
especially when scores are high. Nonetheless, lower FRAX
scores (>10) could also likely indicate increased risk.
According to the American College of Rheumatology
guidelines, preventive antiosteoporotic treatment is
recommended in GC-treated patients >40 years old with
adjusted FRAX values >103. Thus, we observed a trend
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towards subjects with VF more frequently having values
>10 (OR 2.85; 95% CI 1.05 to 7.73, p=0.064).
Our study has some limitations, such as those related to
the cross-sectional nature of the study and the absence of
a control group. In addition, most patients included in
the study had vasculitis or polymyalgia rheumatica, with
isolated cases of RA, thereby limiting the results in
patients with similar clinical characteristics. The low num-
ber of males with hypogonadism could also constitute
a partial limitation in the analysis of this particular sub-
group of patients. Nonetheless, the strengths of this study
include the homogeneity of the patients (all on chronic
GC treatment with doses ≥5 mg/day for autoimmune
disorders), together with in-depth clinical evaluation,
extensive bone metabolism analysis and radiological and
DXA studies related to the development of fractures.
In conclusion, hypogonadism constitutes the principal
risk factor for developing fractures in GC-treated men and
women, highlighting the importance of evaluating gona-
dal status in these patients. Additionally, GC bolus(es) can
be associated with an increased risk of VF, indicating the
need to evaluate this particular risk factor in further pro-
spective studies with concomitant analysis of the inflamma-
tory activity as a confounding risk factor. Evaluation of TBS
and FRAX can improve the identification of high-risk sub-
jects, and thus, the therapeutic approach.
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